Daniel D. Baldwin: Before the Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations United States Senate for a Hearing Entitled “Combating the Opioid Crisis: Exploiting Vulnerabilities in International Mail

The Domestic Methamphetamine Threat Assessment provides a comprehensive strategic assessment of the threat posed to the United States by the trafficking and use of methamphetamine. This report combines federal, state, and local law enforcement reporting; public health data; news reports; and intelligence from other government agencies to assess the methamphetamine...

Synthesis and Characterization of Benzoylfentanyl and Benzoylbenzylfentanyl. Microgram Journal 2018; 15(1-4):1-8.

Demetra Ashley: Before the Judiciary Committee, United States Senate, for a Hearing Entitled, “Oversight of the Ensuring Patient Access and Effective Drug Enforcement Act”

Acting Administrator Robert W. Patterson: Department of Justice/Drug Enforcement Administration Press Conference Announcement of New Tools to Address Opioid Crisis

Neil D. Doherty: Before the House Energy and Commerce Committee, United States House of Representatives, for a Hearing Entitled “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives

The Drug Enforcement Administration’s (DEA) Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin, along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. In 2015, a total of 823 qualified exhibits were...

The 2017 National Drug Threat Assessment (NDTA)1 is a comprehensive strategic assessment of the threat posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. The report combines federal, state, local and tribal law enforcement reporting; public health data; open source reporting; and...

Anthony D. Williams: Before the Senate Caucus on International Drug Control

The Drug Enforcement Administration’s (DEA) Heroin Signature Program (HSP) analyzes several hundred wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.